Search
Phenazocine
go.drugbank.com/drugs/DB13606ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSulodexide
go.drugbank.com/drugs/DB06271ApprovedInvestigationalWithdrawnSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Moricizine
go.drugbank.com/drugs/DB00680ApprovedWithdrawnAn antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...
Fenbendazole
go.drugbank.com/drugs/DB11410InvestigationalVet approvedFenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. … It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and
Amilomotide
go.drugbank.com/drugs/DB05150InvestigationalIt is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients. … CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease.
G17DT Immunogen
go.drugbank.com/drugs/DB04914InvestigationalG17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract.
AIT-034
go.drugbank.com/drugs/DB06106Experimentalnot respond to Neotrofin. … AIT-034 does not induce the production of NGF, and its mechanism of action is therefore believed to be different than Neotrofin.
Linifanib
go.drugbank.com/drugs/DB06080InvestigationalLinifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels
Muraglitazar
go.drugbank.com/drugs/DB06510InvestigationalIt belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.